Description
Antibiotic Resistance (‘ABR’) has featured heavily in the news, and has been a particular concern of the nation’s Chief Medical Officer. ABR has the potential to wipe out the future mortality/longevity improvements we might otherwise reasonably expect from general medical/lifestyle advances. In January 2017 the IFoA set up a working party to model the likely impact of ABR. In this session, members of the working party will present their findings (including plausible future scenarios and mortality/morbidity impacts), and describe the model produced by the working party (with associated UK parameterisation).
Speakers:
Nicola Oliver, Mortality and Longevity Consultant, Medical Intelligence (UK) Ltd.
Ross Hamilton, Pensions Consultant, Willis Towers Watson
Dr Craig Armstrong, Aviva Longevity Research Team.